IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Management of Highly Active Anti-retroviral Therapy-related Hyperlipidemia Among HIV-infected Patients in Taiwan
This study is currently recruiting participants.
Verified January 2017 by Kaohsiung Medical University Chung-Ho Memorial Hospital
Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital
Information provided by (Responsible Party):
Kaohsiung Medical University Chung-Ho Memorial Hospital
ClinicalTrials.gov Identifier:
NCT01697540
First received: September 28, 2012
Last updated: April 27, 2017
Last verified: January 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
- Written informed consent must be obtained before any study specific procedures are undertaken.
- The process of the experiment (brief describe) The patients must come back for follow during 4 to 12 weeks after starting the new therapy. The investigators will follow the patients' lipid profile and any side effects and stop the observation till 36 months after starting the new therapy. The serum level of HIV-VL, CD4, GOT, GPT, triglyceride, cholesterol, HDL-cholesterol, and LDL-cholesterol will be checked every 3 months. The patients' chart and all data will be delinked to protect the patients' right and privacy.
| Condition |
|---|
| HIV |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Tropical Medicine Center (TMC), Kaohsiung Medicine University Hospital (KMUH) |
Resource links provided by NLM:
Further study details as provided by Kaohsiung Medical University Chung-Ho Memorial Hospital:
Eligibility| Ages Eligible for Study: | Child, Adult, Senior |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
HIV/AIDS group
Criteria
Inclusion Criteria:
- HIV-infected patients who receive HAART therapy but have metabolic side effects.
- Age over 20 years old
Exclusion Criteria:
- Abnormal liver function: GOT or GPT 5 times over normal upper limit
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01697540
Please refer to this study by its ClinicalTrials.gov identifier: NCT01697540
Contacts
| Contact: Jih- jin Tsai, MD | 886-7-3121101 ext 6638 | jijits@cc.kmu.edu.tw |
Locations
| Taiwan | |
| Tropical medicine center | Recruiting |
| Kaohsiung, Taiwan | |
| Contact: Jih- Jin Tsai, MD 886-7-3121101 ext 6638 jijits@cc.kmu.edu.tw | |
Sponsors and Collaborators
Kaohsiung Medical University Chung-Ho Memorial Hospital
More Information
| Responsible Party: | Kaohsiung Medical University Chung-Ho Memorial Hospital |
| ClinicalTrials.gov Identifier: | NCT01697540 History of Changes |
| Other Study ID Numbers: |
KMUHIRB-2012-05-05(I) |
| Study First Received: | September 28, 2012 |
| Last Updated: | April 27, 2017 |
ClinicalTrials.gov processed this record on June 22, 2017